* Biora Therapeutics Inc is expected to show a fall in quarterly revenue when it reports results on March 26 for the period ending December 31 2023
* The San Diego California-based company is expected to report a 96.4% decrease in revenue to $5 hundred from $14 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Biora Therapeutics Inc is for a loss of 59 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Biora Therapeutics Inc is $27.80, above its last closing price of $1.19.
This summary was machine generated March 22 at 20:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments